Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Serina Therapeutics (SER) EBITDA (2018 - 2025)

Serina Therapeutics' EBITDA history spans 8 years, with the latest figure at -$6.2 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 11.86% to -$6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$22.2 million, a 114.61% decrease, with the full-year FY2025 number at -$24.0 million, down 40.91% from a year prior.
  • EBITDA hit -$6.2 million in Q4 2025 for Serina Therapeutics, down from -$4.6 million in the prior quarter.
  • Over the last five years, EBITDA for SER hit a ceiling of $1.4 million in Q3 2024 and a floor of -$6.2 million in Q4 2025.
  • Historically, EBITDA has averaged -$2.5 million across 5 years, with a median of -$2.0 million in 2021.
  • The widest YoY moves for EBITDA: up 194.53% in 2024, down 2402.49% in 2024.
  • Tracing SER's EBITDA over 5 years: stood at -$1.9 million in 2021, then grew by 4.55% to -$1.8 million in 2022, then surged by 113.52% to $241000.0 in 2023, then tumbled by 2402.49% to -$5.5 million in 2024, then fell by 11.86% to -$6.2 million in 2025.
  • Business Quant data shows EBITDA for SER at -$6.2 million in Q4 2025, -$4.6 million in Q3 2025, and -$5.6 million in Q2 2025.